AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31601239 — intervention group
Group type: EXPERIMENTAL
Intervention: HemoSphere with HPI used to guide treatment
Number of subjects: 100
Study 31601239 — intervention group
Group type: COMPARATOR
Intervention: HemoSphere with HPI software connected but fully covered (control)
Number of subjects: 100
Study 29659672 — intervention group
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20 18 mg/m2
Number of subjects: 635
Study 29659672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 635
Study 27502583 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet‐mediated, pedometer‐based walking intervention (Taking Healthy Steps)
Number of subjects: 239
Study 27502583 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 239
Study 24491874 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated water-based exercise (HEx)
Number of subjects: 32
Study 24491874 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained habitual activities)
Number of subjects: 32
Study 22632109 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic Prostatectomy
Number of subjects: 400
Study 22632109 — intervention group
Group type: COMPARATOR
Intervention: Open Prostatectomy
Number of subjects: 400
Study 20970650 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 36
Study 20970650 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (Tac)
Number of subjects: 36
Study 22489072 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-item predictive score including age <1 year, epilepsy, congenital/genetic conditions, history of transplant, enteral tube, hemoglobin <10 g/dL, blood culture drawn in the preceding 72 hours
Number of subjects: 564
Study 22489072 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 564
Study 15567879 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist + rFSH
Number of subjects: 82
Study 15567879 — intervention group
Group type: COMPARATOR
Intervention: rFSH alone
Number of subjects: 82
Study 14526713 — intervention group
Group type: EXPERIMENTAL
Intervention: EPs 7630 (20 drops tid for 6 days)
Number of subjects: 143
Study 14526713 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 drops tid for 6 days)
Number of subjects: 143
Study 14526713 — intervention group
Group type: COMPARATOR
Intervention: EPs 7630 vs Placebo
Number of subjects: 143
Study 14526713 — intervention group
Group type: EXPERIMENTAL
Intervention: EPs 7630
Number of subjects: 143
Study 14526713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 10586932 — intervention group
Group type: EXPERIMENTAL
Intervention: Etafilcon A lens
Number of subjects: 20
Study 10586932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafilcon A lens
Number of subjects: 20
Study 10586932 — intervention group
Group type: COMPARATOR
Intervention: Control eyes paired with Etafilcon A lens
Number of subjects: 20
Study 10586932 — intervention group
Group type: COMPARATOR
Intervention: Control eyes paired with Lotrafilcon A lens
Number of subjects: 20
Study 8901789 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 g Brussels sprouts/d for 3 weeks
Number of subjects: 0
Study 8901789 — intervention group
Group type: COMPARATOR
Intervention: 150 mg eugenol/d in capsule form
Number of subjects: 0
Study 1876744 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 1% 40 ml + phentanyl 100 micrograms
Number of subjects: 60
Study 1876744 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 1% 40 ml + subcutaneous phentanyl 100 micrograms
Number of subjects: 60
Study 1876744 — intervention group
Group type: COMPARATOR
Intervention: Mepivacaine 1% 40 ml (control group)
Number of subjects: 60
Study 6283645 — intervention group
Group type: EXPERIMENTAL
Intervention: tiapride (900 mg per day for three months)
Number of subjects: 25
Study 6283645 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study 6283645 — intervention group
Group type: EXPERIMENTAL
Intervention: tiapride
Number of subjects: 25
Study 29437181 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive intervention (motivational interviewing within a web-based health risk assessment)
Number of subjects: 491
Study 29437181 — intervention group
Group type: COMPARATOR
Intervention: Limited intervention (web-based health risk assessment only)
Number of subjects: 491
Study 29437181 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive intervention (motivational interviewing)
Number of subjects: 491
Study 27143213 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 220 mg once daily (starting with 110 mg half-dose, 1-4 hours after surgery)
Number of subjects: 179
Study 27143213 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily (starting the evening before surgery)
Number of subjects: 179
Study 27143213 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 179
Study 27143213 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 179
Study 27143213 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran and Enoxaparin
Number of subjects: 179
Study 26121789 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic electrolyte solution with 1% glucose (IT)
Number of subjects: 50
Study 26121789 — intervention group
Group type: COMPARATOR
Intervention: Hypotonic electrolyte solution with 2.6% glucose (HT)
Number of subjects: 50
Study 23796291 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 15212
Study 23796291 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 15212
Study 20572419 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 40
Study 20572419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18424323 — intervention group
Group type: EXPERIMENTAL
Intervention: ISA247 0.2 mg/kg
Number of subjects: 451
Study 18424323 — intervention group
Group type: EXPERIMENTAL
Intervention: ISA247 0.3 mg/kg
Number of subjects: 451
Study 18424323 — intervention group
Group type: EXPERIMENTAL
Intervention: ISA247 0.4 mg/kg
Number of subjects: 451
Study 18424323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study 16844623 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte filter (LeukoGuard LG6)
Number of subjects: 20
Study 16844623 — intervention group
Group type: COMPARATOR
Intervention: Control group (without leukocyte filter)
Number of subjects: 20
Study 12925471 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate 0.2 mg kg(‐1)
Number of subjects: 30
Study 12925471 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg kg(‐1)
Number of subjects: 30
Study 12925471 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate 0.4 mg kg(‐1)
Number of subjects: 30
Study 10683103 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation (5 g of Cr plus 1 g of sucrose 4x per day)
Number of subjects: 17
Study 10683103 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 g of sucrose placebo 4x per day)
Number of subjects: 17
Study 10683103 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation
Number of subjects: 17
Study 10683103 — intervention group
Group type: COMPARATOR
Intervention: Creatine (Cr) supplementation and Placebo
Number of subjects: 17
Study 8877825 — intervention group
Group type: EXPERIMENTAL
Intervention: Notetaking
Number of subjects: 118
Study 8877825 — intervention group
Group type: EXPERIMENTAL
Intervention: Essay writing
Number of subjects: 118
Study 8877825 — intervention group
Group type: COMPARATOR
Intervention: No writing (Control)
Number of subjects: 118
Study 1799190 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxitalamate
Number of subjects: 60
Study 1799190 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 60
Study 1799190 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 60
Study 1799190 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 60
Study 6630548 — intervention group
Group type: EXPERIMENTAL
Intervention: Faking groups (Right, Left, Diffuse, Nonspecific)
Number of subjects: 254
Study 6630548 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 254
Study 30357297 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol (40 mg/kg every 12 hours for up to 10 weeks)
Number of subjects: 638
Study 30357297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 638
Study 30357297 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol
Number of subjects: 638
Study 26846898 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical trainee research collaboratives
Number of subjects: 24
Study 26846898 — intervention group
Group type: EXPERIMENTAL
Intervention: Publications from surgical trainee research collaboratives
Number of subjects: 24
Study 24910270 — intervention group
Group type: EXPERIMENTAL
Intervention: Undecylenoyl phenylalanine 2%
Number of subjects: 40
Study 24910270 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 40
Study 23083952 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 71
Study 23083952 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 71
Study 23083952 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 71
Study 19828909 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin therapy
Number of subjects: 591
Study 18441040 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy (CIMT)
Number of subjects: 30
Study 18441040 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation (Control)
Number of subjects: 30
Study 15706548 — intervention group
Group type: EXPERIMENTAL
Intervention: Positioning the affected shoulder in maximum comfortable external rotation for 30 minutes, 5 days a week, for 4 weeks.
Number of subjects: 31
Study 15706548 — intervention group
Group type: EXPERIMENTAL
Intervention: Positioning the affected shoulder in 90 degrees of flexion for 30 minutes, 5 days a week, for 4 weeks.
Number of subjects: 31
Study 11900495 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program based on behavioral theory and practice with standardized patients
Number of subjects: 251
Study 10200742 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 50 mg/day
Number of subjects: 242
Study 10200742 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 100 mg/day
Number of subjects: 242
Study 10200742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 8848950 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (400-600 mg/day)
Number of subjects: 191
Study 8848950 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine (100-150 mg/day)
Number of subjects: 191
Study 2330930 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rhesus rotavirus vaccine at a dose of 10(4) plaque‐forming units
Number of subjects: 114
Study 2330930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 45412 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary bypass surgery
Number of subjects: 100
Study 45412 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 100
Study 45412 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization
Number of subjects: 100
Study 45412 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete revascularization
Number of subjects: 100
Study 30529686 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition with two control responses
Number of subjects: 20
Study 30529686 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition with four control responses
Number of subjects: 20
Study 30529686 — intervention group
Group type: COMPARATOR
Intervention: Control responses (inactive control response)
Number of subjects: 20
Study 28938896 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial injury in proliferative phase (group A, n = 38)
Number of subjects: 142
Study 28938896 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial injury in luteal phase (group B, n = 32)
Number of subjects: 142
Study 28938896 — intervention group
Group type: COMPARATOR
Intervention: Non-injury in proliferative phase (group C, n = 36)
Number of subjects: 142
Study 28938896 — intervention group
Group type: COMPARATOR
Intervention: Non-injury in luteal phase (group D, n = 36)
Number of subjects: 142
Study 25652873 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H5N1 influenza vaccine (1·9 μg or 3·75 μg hemagglutinin antigen)
Number of subjects: 405
Study 25652873 — intervention group
Group type: COMPARATOR
Intervention: Seasonal trivalent influenza vaccine
Number of subjects: 405
Study 23204169 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A virus (HAV) vaccine
Number of subjects: 0
Study 23204169 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 21454745 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot (BR) juice
Number of subjects: 8
Study 21454745 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 8
Study 19101234 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss during hospitalization (average 3.6 kg)
Number of subjects: 433
Study 19101234 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss categorized into 3 tertiles
Number of subjects: 433
Study 19101234 — intervention group
Group type: EXPERIMENTAL
Intervention: Days alive out of the hospital in the first 6 months
Number of subjects: 433
Study 19101234 — intervention group
Group type: EXPERIMENTAL
Intervention: 180-day death
Number of subjects: 433
Study 19101234 — intervention group
Group type: EXPERIMENTAL
Intervention: Death or rehospitalization at 180 days
Number of subjects: 433
Study 17786744 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment criteria available for reference on the medical school website
Number of subjects: 0
Study 17786744 — intervention group
Group type: EXPERIMENTAL
Intervention: Students received the assessment criteria for use in discussion and feedback
Number of subjects: 0
Study 17786744 — intervention group
Group type: EXPERIMENTAL
Intervention: Students graded their own performance, peer assessment, tutor assessment, and actor assessment using standard assessment criteria
Number of subjects: 0
Study 15572199 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycine eye drops alone or in combination with cyclosporine A, diclofenac, or rimexolone
Number of subjects: 0
Study 15572199 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimexolone
Number of subjects: 0
Study 15572199 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous humor from uninflamed human
Number of subjects: 0
Study 15572199 — intervention group
Group type: COMPARATOR
Intervention: Aqueous humor from rabbit
Number of subjects: 0
Study 11759134 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing a video demonstrating pediatric mask induction (group 1; n = 40)
Number of subjects: 80
Study 11759134 — intervention group
Group type: COMPARATOR
Intervention: Information pamphlet only (group 2; n = 40)
Number of subjects: 80
Study 9921608 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 0
Study 9921608 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 7702060 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid (1.5 g twice a day)
Number of subjects: 12
Study 7702060 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg/d)
Number of subjects: 12
Study 2198822 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin-G (IVIG)
Number of subjects: 0
Study 904877 — intervention group
Group type: EXPERIMENTAL
Intervention: Iris-clip lens implants
Number of subjects: 46
Study 904877 — intervention group
Group type: COMPARATOR
Intervention: Intracapsular lens extraction
Number of subjects: 46
Study 31238203 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) diagnosis
Number of subjects: 125
Study 31238203 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, male sex, and higher Body Mass Index (BMI)
Number of subjects: 125
Study 31238203 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime sleepiness and insomnia
Number of subjects: 125
Study 27987094 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine rinses (0.15%)
Number of subjects: 120
Study 27987094 — intervention group
Group type: COMPARATOR
Intervention: Control chemoradiotherapy (saline mouth rinses)
Number of subjects: 120
Study 26048185 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/metformin XR FDC tablets (5 mg/500 mg in study 1; 10 mg/1000 mg in study 2)
Number of subjects: 0
Study 26048185 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/metformin XR FDC tablets (administered with a light-fat meal)
Number of subjects: 0
Study 26048185 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/metformin XR FDC tablets
Number of subjects: 0
Study 23354187 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine heparin R‐AHD
Number of subjects: 10
Study 23354187 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose heparin R‐AHD
Number of subjects: 10
Study 23354187 — intervention group
Group type: COMPARATOR
Intervention: Routine heparin DNHD (control)
Number of subjects: 10
Study 23354187 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine heparin-mixed AHD PR
Number of subjects: 10
Study 21653990 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss and low-intensity exercise program (WL+LEX)
Number of subjects: 35
Study 19342867 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (n = 15)
Number of subjects: 45
Study 19342867 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (n = 15)
Number of subjects: 45
Study 19342867 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 45
Study 16188495 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 64
Study 12821546 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE-covered JoStent coronary stent graft
Number of subjects: 301
Study 12821546 — intervention group
Group type: COMPARATOR
Intervention: SS JoFlex stent (control)
Number of subjects: 301
Study 10687746 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 15
Study 10687746 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of propofol
Number of subjects: 15
Study 10687746 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep anesthetic level with propofol
Number of subjects: 15
Study 10687746 — intervention group
Group type: COMPARATOR
Intervention: Thiamylal (control)
Number of subjects: 15
Study 8932015 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-fluidised bed therapy at 32 degrees C (Group B)
Number of subjects: 14
Study 8932015 — intervention group
Group type: COMPARATOR
Intervention: Standard intensive care unit bed at 22 degrees C (Group A)
Number of subjects: 14
Study 1873204 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral therapy (8-methoxypsoralen)
Number of subjects: 20
Study 1873204 — intervention group
Group type: EXPERIMENTAL
Intervention: Bath treatment (8-methoxypsoralen)
Number of subjects: 20
Study 1873204 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study 6355795 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole and Cephamandole
Number of subjects: 211
Study 6355795 — intervention group
Group type: COMPARATOR
Intervention: Tinidazole and Placebo
Number of subjects: 211
Study 6355795 — intervention group
Group type: COMPARATOR
Intervention: Tinidazole alone
Number of subjects: 211
Study 6355795 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (Tinidazole and Cephamandole)
Number of subjects: 211
Study 3905469 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 12
Study 3905469 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 12
Study 30326639 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dairy intake (−14.6 ± 3.0 g/day)
Number of subjects: 102
Study 30326639 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintained dairy intake (−4.0 ± 2.0 g/day)
Number of subjects: 102
Study 30326639 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dairy intake (+13.8 ± 4.1 g/day)
Number of subjects: 102
Study 30326639 — intervention group
Group type: COMPARATOR
Intervention: All groups (reduced, maintained, increased)
Number of subjects: 102
Study 26764321 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g LNS (Lipid-Based Nutrient Supplement)
Number of subjects: 1320
Study 26764321 — intervention group
Group type: COMPARATOR
Intervention: 60 mg iron + 400 μg folic acid (IFA)
Number of subjects: 1320
Study 26764321 — intervention group
Group type: COMPARATOR
Intervention: Multiple micronutrients (MMNs)
Number of subjects: 1320
Study 25496514 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT/CBT
Number of subjects: 120
Study 25496514 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoid/CBT
Number of subjects: 120
Study 25496514 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 120
Study 22555894 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone 1 mg/kg/d (tapered gradually)
Number of subjects: 48
Study 22555894 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapolyp injection of triamcinolone acetonide (0.3 mL, 40 mg/mL)
Number of subjects: 48
Study 22555894 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical triamcinolone acetonide (55 µg, 2 times daily for 1 month)
Number of subjects: 48
Study 22555894 — intervention group
Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 48
Study 22555894 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone vs Topical triamcinolone
Number of subjects: 48
Study 22555894 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapolyp injection vs Oral methylprednisolone
Number of subjects: 48
Study 22555894 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapolyp injection vs Topical triamcinolone
Number of subjects: 48